Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | WRN | Q14191 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10147986 | 0.89 | HPGD (0.45) | HPGDALDH1A1SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL19116912 | 0.89 | HPGD (0.45) | HPGDALDH1A1SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL4761616 | 0.86 | SMN1; SMN2 (0.49) | ALDH1A1CYP2C19SMN1; SMN2KDM4ECYP2D6 | |
| SCHEMBL890523 | 0.86 | CTH (0.39) | HPGDALDH1A1CYP1A2CYP2C19BLM | |
| SCHEMBL18165220 | 0.86 | CTH (0.39) | HPGDALDH1A1CYP1A2CYP2C19BLM | |
| SCHEMBL11990499 | 0.85 | SMN1; SMN2 (0.53) | ALDH1A1SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL12092098 | 0.85 | LMNA (0.47) | HPGDALDH1A1CYP1A2CYP2C19BLM | |
| SCHEMBL20434520 | 0.85 | EPHX2 (0.44) | HPGDALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL18461344 | 0.85 | SMN1; SMN2 (0.42) | HPGDALDH1A1CYP1A2CYP2C19BLM | |
| SCHEMBL14872066 | 0.84 | NAAA (0.55) | ALDH1A1SMN1; SMN2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219962-A1 | PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | MERCK SHARP & DOHME LLC (US) | 2023-07-13 | — | — | US | disclosed |
| WO-2021143741-A1 | TARGETING POLYPEPTIDE-DRUG CONJUGATE AND USE THEREOF | 北京海步医药科技有限公司 | 2021-07-22 | — | — | WO | disclosed |
| US-9850318-B2 | Antibodies to quetiapine haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-26 | — | — | US | disclosed |
| US-20170043020-A1 | ANTIBODY-MEDIATED DISRUPTION OF QUORUM SENSING IN BACTERIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-16 | — | — | US | disclosed |
| US-9394371-B2 | Antibody-mediated disruption of quorum sensing in bacteria | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394371-B2 | Antibody-mediated disruption of quorum sensing in bacteria | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-07-19 | — | — | US | disclosed |
| US-9102735-B2 | Immunoconjugates with an intracellularly-cleavable linkage | IMMUNOMEDICS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-8835556-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | NEKTAR THERAPEUTICS (US) | 2012-09-06 | — | — | US | disclosed |
| US-8227555-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2012-07-24 | — | — | US | disclosed |
| US-20100291093-A1 | ANTIBODY-MEDIATED DISRUPTION OF QUORUM SENSING IN BACTERIA | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-18 | — | — | US | disclosed |
| US-20090012241-A1 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012241-A1 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-01-08 | — | — | US | disclosed |
| US-7432330-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432330-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432331-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432331-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080171067-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | IMMUNOMEDICS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080171067-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | IMMUNOMEDICS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| WO-2008028206-A2 | METHOD FOR PRODUCING REACTIVE MONOLAYER UNITS | Universität Linz (AT) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170043020-A1 | ANTIBODY-MEDIATED DISRUPTION OF QUORUM SENSING IN BACTERIA | CD47, TLR5, ANTXR2 | HPGD 4204/4885ALDH1A1 4584/4885CYP1A2 4867/4885 |
| US-20230219962-A1 | PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | DPYD, TYMP, TK1 | HPGD 348/4885ALDH1A1 436/4885CYP1A2 2125/4885 |
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | PADI6, MPI, VIM | HPGD 1203/4885ALDH1A1 1089/4885CYP1A2 2806/4885 |
| US-20080171067-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | CD47, BSG, SELPLG | HPGD 1352/4885ALDH1A1 3965/4885CYP1A2 4853/4885 |
| US-20100291093-A1 | ANTIBODY-MEDIATED DISRUPTION OF QUORUM SENSING IN BACTERIA | CD47, BCR, TLR5 | HPGD 4461/4885ALDH1A1 4701/4885CYP1A2 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.